

#### **DISCLAIMER**

This presentation contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Group as of the date such statements are made. Forward-looking statements are neither historical facts nor assurances of future performance. They may, but need not, be identified by words such as: "anticipate," "intend," "plan," "goal," "believe," "project," "estimate," "expect," "future," "likely," "may," "should," "will" and similar references to future periods or events. Such forward-looking statements reflect the views, beliefs, assumptions and expectations of Straumann Group or its management at the time the statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may be outside of Straumann Group's control. Such known and unknown risks, uncertainties and other factors underlying forward-looking statements may cause the actual results, performance or achievements of the Group to differ materially from those expressed or implied in this presentation. Accordingly, you should not rely on any forward-looking statements contained in this presentation. Important factors that could cause the Group's not rely on any forward-looking statements contained in this presentation. Important factors that could cause the Group's expectations regarding future results, performance or achievements to differ materially from those expressed in a forwardlooking statement include, but are not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann Group's control. Should one or more of these risks, uncertainties or other factors materialize or should underlying views, beliefs, assumptions or expectations prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann Group is providing the information in this presentation as of the date it is given and does not undertake any obligation to update any statements as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities.

# **AGENDA**

Highlights	Guillaume Daniellot	
Financials	Isabelle Adelt	
Recent achievements & strategy	Guillaume Daniellot	
Outlook 2025	Guillaume Daniellot	
Q&A	Guillaume Daniellot, Isabelle Adelt	



### STRONG 8.3 % ORGANIC GROWTH AND OUTLOOK CONFIRMED

Third-quarter revenue in 2025 <sup>1</sup>

602.0 m

Nine-month: 2.0 billion <sup>1</sup>

Organic revenue growth 1,2

8.3%

Nine-month: 9.6% 1, 2

Orthodontics transformation

# Smartee global partnership

Additional partnership with DentalMonitoring

**Innovation** 

#### **New SIRIOS X3**

New intraoral scanner integrated into AXS

China

# Campus inaugurated and in full production

Strengthening supply chain resilience ahead of VBP 2.0 in China

Outlook 2025 confirmed<sup>3</sup>

High-single digit organic revenue growth


with 30 to 60 basis points improvement of the core EBIT margin at constant 2024 currency rates

<sup>&</sup>lt;sup>1</sup> Financials refer to continuous operations

<sup>&</sup>lt;sup>2</sup> Organic growth excluding FX and M&A effects

#### STRONG PERFORMANCE – REGIONAL DIFFERENCES REMAIN

Organic revenue growth in the third quarter




GROUP Q3 25 8.3% Q3 24 11.2%



#### STRONG RESULTS WITH CONSIDERABLE FX HEADWINDS

Revenue development breakdown (in CHF million, rounded)



#### **TARIFFS MITIGATION EFFORTS**

#### 2025

#### Inventory build-up and supply flexibility

- Stock increases in key markets to secure continuity
- Adjusted logistics flows to mitigate near-term cost impact

#### 2026

#### Local production and supply chain optimization

- Increased share of locally produced finished products
- Local assembly and packaging line implemented to reduce tariff exposure and improve supply efficiency

#### Actively implemented mitigation measures to counter the effects of tariffs

#### REINVESTING WHERE RETURN ON CAPITAL IS HIGHEST

Capital allocation priority order

- 1 Reinvest in sustainable business growth
  - 2 Maintain strong balance sheet
  - 3 Pursue M&A to accelerate strategy
- 4 Maintain and increase dividend with earnings growth




**Guillaume Daniellot, CEO** 



## **HUGE OPPORTUNITIES - IMPLANTOLOGY & BEYOND**

Addressable market of about CHF 20bn globally




MARKET SHARE GROWTH THROUGH INNOVATION

### TRANSFORM OUR ORTHO BUSINESS FOR COMPETITIVENESS

New partnership with Smartee to strengthen value proposition and profitability

#### **Smartee**<sup>®</sup>




- Smartee is a leading clear aligner company and innovation partner with strong presence in Asia
- Accelerates our value proposition covering broader coverage of indications
- Improves manufacturing efficiency and cost structure through fully automated production

#### TRANSFORMING CLEARCORRECT'S VALUE PROPOSITION


# Al monitoring expanding GP adoption **Dental Monitoring** Smarter Orthodontics Powered by DentalMonitoring and seamlessly integrated into the ClearCorrect Doctor Portal.

# Advances software & new clinical features



New treatment outcome simulation and mandibular advancement.

## STRAUMANN INNOVATION DRIVING PREMIUM IMPLANTOLOGY






#### EDUCATION AS A KEY DRIVER TO CAPTURE MARKET SHARE

EAO, Esthetic Days and DSO CEO Summit














## LAUNCH OF NEW X3 INTRAORAL SCANNER

- Lightweight
- High scanning speed
- Straumann AXS™ cloud connected





## DRIVING EFFICIENCY THROUGH NEWLY LAUNCHED DIGITAL WORKFLOWS



#### **Full-Arch: Straumann EXACT digital impression solution**




#### STRENGTHENING OUR POSITION IN CHINA AHEAD OF VBP 2.0




- Shanghai campus ramp-up completed; first local production
- Local manufacturing driving efficiency
- Multi-brand strategy expanding market access including new local eco-brand developed in partnership
- Offering education programs to advance implantology skills in China

## **EMPOWERING SMILES THROUGH OUR CULTURE OF CARE**



# Smile Movement 5 000+ employees united for a cause





#### **CONFIRMED OUTLOOK 2025**

Barring unforeseen circumstances

# Market environment and assumption

- Uncertain economic environment remains
- Group believes global patient flow should remain stable
- Continue to outgrow market

#### **Revenue and profitability**

- Organic revenue growth in the high single-digit percentage range
- With 30 to 60 basis points improvement of the core EBIT margin at constant 2024 currency rates





## **CALENDAR OF UPCOMING EVENTS**

2025	Event	Location
4 – 5 November	J.P. Morgan UK Roadshow	London
5 November	ZKB Swiss Equity Conference	Zurich
6 November	ODDO Germany Roadshow	Frankfurt
25 November	Capital Markets Day	Basel & Webcast
2 December	Citi Global HC Conference	Miami
3 December	Evercore HC Conference	Miami
1 Jan – 17 Feb 2026	Quiet period	
18 February 2026	Full-Year 2025 Results	Webcast